Creative Medical Technology Holdings, Inc. (CELZ)
NASDAQ: CELZ · Real-Time Price · USD
2.500
-0.010 (-0.40%)
At close: Jul 16, 2025, 4:00 PM
2.648
+0.148 (5.93%)
After-hours: Jul 16, 2025, 5:34 PM EDT
CELZ Employees
Creative Medical Technology Holdings had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$3,500
Profits / Employee
-$1,522,509
Market Cap
6.45M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CELZ News
- 5 days ago - Creative Medical Technology Holdings Receives Notice of Allowance for ImmCelz™ for Treatment of Heart Failure and/or Post Infarct Pathological Remodeling - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain - GlobeNewsWire
- 4 months ago - Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™ - GlobeNewsWire
- 5 months ago - Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development - GlobeNewsWire
- 5 months ago - Creative Medical Technology Holdings Announces Positive Initial Safety, Tolerability, and Efficacy Data from First Cohort in Phase 1/2 Trial of CELZ-201-DDT for Chronic Back Pain - GlobeNewsWire
- 8 months ago - Top 3 Real Estate Stocks That May Explode In Q4 - Benzinga